The Mayo Clinic and Exact Sciences are developing an easy, noninvasive test to detect endometrial cancer in women with ...

A comparison of patients with and without BRCA gene mutations receiving prophylactic risk-reduction surgery suggest ...

Evolution in women's cancer diagnostics: from histopathology to molecular testing, personalized treatment for breast, ovarian ...

Acrivon has developed its AP3 Interactome, a proprietary, computational analytics platform driven by Generative ...

Charles Schwab Investment Management Inc. boosted its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – ...

In RUBY, Jemperli reduced the risk of disease progression or death by 72% in patients with primary advanced or recurrent endometrial ... and 20% with serous carcinoma - particularly aggressive ...

“We previously identified endometrial cancer as a sensitive tumor type with ... with aggressive histopathologies (75% serous or carcinosarcomas), pMMR, and p53 mutations, we observed strong ...

Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 ...

"We previously identified endometrial cancer as a sensitive tumor type with ... with aggressive histopathologies (75% serous or carcinosarcomas), pMMR, and p53 mutations, we observed strong ...